Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Labetalol
Drug ID BADD_D01236
Description Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture.[L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Indications and Usage Labetalol injections are indicated to control blood pressure in severe hypertension.[L7727] Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.[L7730]
Marketing Status approved
ATC Code C07AG01
DrugBank ID DB00598
KEGG ID D08106
MeSH ID D007741
PubChem ID 3869
TTD Drug ID D0A8XN
NDC Product Code 10135-713; 10135-711; 10135-712
UNII R5H8897N95
Synonyms Labetalol | Labetolol | Albetol | Apo-Labetalol | Apo Labetalol | ApoLabetalol | Trandate | Labetalol Hydrochloride | Hydrochloride, Labetalol | Normodyne | Presolol | SCH-19927 | SCH 19927 | SCH19927 | AH-5158 | AH 5158 | AH5158 | Dilevalol | Labetalol, (R,R)-Isomer | R,R-Labetalol | R,R Labetalol
Chemical Information
Molecular Formula C19H24N2O3
CAS Registry Number 36894-69-6
SMILES CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Irritability08.01.03.011; 19.04.02.0130.000244%
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Jaundice cholestatic09.01.01.005---
Joint swelling15.01.02.004---
Laryngospasm22.04.02.002--
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Lichen planus23.03.08.001---
Liver function test abnormal13.03.04.030---
Loss of consciousness17.02.04.004---
Loss of libido19.08.03.003---
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.0030.000163%
Mesenteric artery thrombosis07.15.02.008; 24.01.08.003---
Mood swings19.04.03.001---
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.0090.000325%
Myopathy toxic12.03.01.035; 15.05.05.006---
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neurotoxicity12.03.01.011; 17.02.10.0020.000325%-
Nightmare19.02.03.003---
Nipple pain21.05.05.0090.000325%-
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Orthostatic hypotension17.05.01.020; 24.06.03.004---
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pallor08.01.03.032; 23.03.03.031; 24.03.04.0010.000163%-
Palpitations02.11.04.012--
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene